替考拉宁
病危
医学
药效学
加药
药代动力学
重症监护医学
内科学
万古霉素
遗传学
生物
细菌
金黄色葡萄球菌
作者
Ling Wang,Mingguang Chen,Hong Ye,Xiaolan Lin,Yixuan Li,Junshan Ruan,Fenghui Lin,Yuxing Lin
出处
期刊:Current Drug Metabolism
[Bentham Science]
日期:2021-12-01
卷期号:22 (14): 1124-1131
标识
DOI:10.2174/1389200222666211122124420
摘要
Significant changes in the pathophysiology of older critically ill patients may affect the pharmacokinetics and pharmacodynamics of teicoplanin. This study aimed to determine the optimal teicoplanin blood level in this patient population.128 older critically ill and 86 older non-critically ill patients were involved and analyzed.The target thresholds of teicoplanin blood concentrations in older critically ill patients and non-critically ill patients should be 31.4mg/L and 15.3mg/L, respectively. The dose of teicoplanin in older critically ill patients should be greater than 800 mg to achieve the target blood level.An individualized dosing approach of teicoplanin based on therapeutic drug monitoring is necessary for older critically ill patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI